As World Awaits Results From Remdesivir Trials, Pricing Questions Loom

post-default-image
April 9

Hydroxychloroquine and chloroquine are far from the only drugs being tested for their potential to treat COVID-19, the disease caused by the novel coronavirus that has ballooned into a pandemic.

Another potentially promising therapy is remdesivir, an experimental antiviral drug developed by California-based Gilead Sciences, Inc. Previously, it has been tested on patients infected with Ebola and two other coronaviruses: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).

0
0 Comments
© 2023 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

pills-in-hands
June 8

Buprenorphine Coverage Is Improving, but Access Barriers Remain

READ MORE
a-businessman-touching-tablet-screen
June 8

CVS Exec Says Employers ‘Shape the Economics’ of PBMs

READ MORE
an-old-lady-at-the-pharmacy
June 8

Community Pharmacist Group Greets Optum Rx Programs With Cautious Optimism

READ MORE

The Latest

Premium Categories

enhance-patient-assistance-programs

Meet Our Reporters

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today